Table 2.

Incidence of most common (>20%) of treatment-emergent AEs independent of relationship

All grades (n = 21)600 mg QD + DT (n = 3)600 mg QD (n = 8)750 mg QD(n = 9)900 mg QD(n = 1)
Adverse eventaGr 1–3Gr 1–2Gr 3Gr 1–2Gr 3Gr 1–2Gr 3Gr 1–2Gr 3
Fatigue15 (71)2 (67)0 (0)6 (75)1 (13)6 (67)0 (0)1 (100)0 (0)
Dizziness11 (52)2 (67)0 (0)4 (50)0 (0)4 (44)0 (0)1 (100)0 (0)
Blurred vision8 (38)1 (33)0 (0)2 (25)0 (0)4 (44)0 (0)1 (100)0 (0)
Dysgeusia7 (33)2 (67)0 (0)1 (13)0 (0)4 (44)0 (0)0 (0)0 (0)
Constipation6 (29)1 (33)0 (0)2 (25)0 (0)3 (33)0 (0)0 (0)0 (0)
Disturbance in attention6 (29)2 (67)0 (0)2 (25)0 (0)1 (11)0 (0)1 (100)0 (0)
Tremor6 (29)1 (33)0 (0)0 (0)0 (0)4 (44)0 (0)1 (100)0 (0)
Memory impairment5 (24)2 (67)0 (0)0 (0)0 (0)3 (33)0 (0)0 (0)0 (0)
Muscular weakness5 (24)1 (33)0 (0)1 (13)0 (0)2 (22)0 (0)0 (0)1 (100)
Tachycardia5 (24)1 (33)0 (0)2 (25)0 (0)1 (11)0 (0)1 (100)0 (0)
Nausea5 (24)2 (67)0 (0)2 (25)0 (0)1 (11)0 (0)0 (0)0 (0)
Vomiting5 (24)0 (0)0 (0)3 (38)0 (0)2 (22)0 (0)0 (0)0 (0)
  • Abbreviations: DT, dose titration; Gr, grade; QD, once daily.

  • an (%).